Premenstrual Dysphoric Disorder

Complex MONDO:1010182 Pathograph 8 Show in embeddings browser Psychiatric Disease Mood Disorder

Premenstrual dysphoric disorder (PMDD) is a severe, cyclical mood disorder in which clinically significant affective and somatic symptoms emerge during the luteal phase of the menstrual cycle (roughly the week before menstruation), remit within a few days of the onset of bleeding, and are essentially absent in the follicular phase. PMDD is not a state of abnormal circulating hormone levels: estradiol and progesterone cycle normally. Instead it reflects an abnormal central nervous system sensitivity to the normal cyclical fluctuation of ovarian steroids, so the trigger is a physiological hormonal change that unaffected people tolerate without mood disturbance. It was added as a distinct diagnostic category in the depressive disorders section of DSM-5 (2013) and is diagnosed by prospective daily symptom ratings across at least two cycles rather than by any biomarker or imaging test. PMDD affects people with ovulatory menstrual cycles during their reproductive years.

Ask OpenScientist

Ask a research question about Premenstrual Dysphoric Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
5
Pathophys.
13
Phenotypes
2
Hypotheses
1
Gaps
8
Pathograph
4
Genes
5
Medical Actions
3
Differentials
1
Trials
5
References
1
Deep Research
🏷

Classifications

Harrison's Chapter
NEUROLOGIC
👪

Inheritance

1
Multifactorial HP:0010982
PMDD is multifactorial/polygenic. Twin studies estimate substantial heritability of the stable trait component of premenstrual symptoms, with the genetic risk largely distinct from that of major depression. No Mendelian pattern, penetrance, or anticipation applies.
Polygenic inheritance
Show evidence (2 references)
PMID:9734548 SUPPORT Human Clinical
"The best-fitting twin-measurement model estimated the heritability of the stable component of premenstrual symptoms at 56% and showed no impact of family-environmental factors."
Provides the heritability estimate (56%) for the stable component of premenstrual symptoms.
PMID:9734548 SUPPORT Human Clinical
"The genetic and environmental risk factors for these premenstrual symptoms and lifetime major depression are not closely related."
Shows the genetic liability for premenstrual symptoms is largely distinct from that of major depression.
◈

Mechanistic Hypotheses

2
Allopregnanolone-GABA-A Receptor Sensitivity Model
allopregnanolone_gabaa_sensitivity CANONICAL
The dominant mechanistic model holds that PMDD results from impaired GABA-A receptor adaptation to the normal luteal fluctuation of the progesterone metabolite allopregnanolone, producing a failure of inhibitory neurotransmission and downstream corticolimbic dysregulation. This model motivates neurosteroid- and GABA-A-targeted drug development (e.g., sepranolone).
Show evidence (1 reference)
PMID:36937732 SUPPORT Other
"PMDD pathophysiology is rooted in GABAA receptor sensitivity changes caused by rapid changes in ALLO levels."
States the canonical allopregnanolone-GABA-A sensitivity model.
ESC/E(Z) Epigenetic Set-Point Model
esc_ez_epigenetic_setpoint EMERGING
An emerging molecular model proposes that intrinsic dysregulation of the ESC/E(Z) chromatin-silencing complex sets the heritable abnormal cellular response to ovarian steroids that underlies PMDD. Evidence is from patient- derived lymphoblastoid cells; the link to brain mood circuitry is unproven.
Show evidence (1 reference)
PMID:28044059 SUPPORT In Vitro
"Dysregulation of ESC/E(Z) complex function could contribute to PMDD."
States the emerging ESC/E(Z) epigenetic contribution to PMDD.
?

Discussions and Knowledge Gaps

1
Does the intrinsic ESC/E(Z) epigenetic dysregulation observed in patient-derived lymphoblastoid cell lines causally drive the abnormal ovarian-steroid sensitivity of brain mood circuitry in PMDD, or is it a peripheral correlate without a direct role in the central pathophysiology?
KNOWLEDGE GAP OPEN gap_pmdd_escez_brain_translation
Attached to
pathophysiology#ESC/E(Z) Epigenetic Dysregulation pathophysiology#Abnormal Sensitivity to Cyclic Ovarian Steroids
The ESC/E(Z) finding is the strongest molecular lead for the heritable steroid-sensitivity trait, but it was discovered in peripheral lymphoblastoid cells. Whether the same epigenetic difference operates in the corticolimbic neurons that generate mood symptoms, and whether it mechanistically sets the GABA-A/allopregnanolone sensitivity defect, is unknown. Resolving this would determine whether ESC/E(Z) is a tractable central target or a biomarker.
Show evidence (1 reference)
PMID:28044059 SUPPORT In Vitro
"These findings demonstrate that LCLs from women with PMDD manifest a cellular difference in ESC/E(Z) complex function both in the untreated condition and in response to ovarian hormones."
The cellular difference is demonstrated in peripheral LCLs, leaving open its relevance to brain mood circuitry.
⚙

Pathophysiology

5
Abnormal Sensitivity to Cyclic Ovarian Steroids
The proximate cause of PMDD is an abnormal central nervous system response to the normal luteal-phase fluctuation of ovarian steroids, not abnormal hormone levels. In the landmark NIMH experiment, suppressing ovarian function with the GnRH agonist leuprolide abolished symptoms in affected individuals, and adding back estradiol or progesterone reintroduced them, whereas unaffected individuals showed no mood change to the identical manipulation. This differential sensitivity is the unifying mechanistic frame for the disorder.
Neuron CL:0000540
Response to Progesterone GO:0032570 Steroid Hormone Receptor Signaling GO:0043401
Downstream
Allopregnanolone-GABA-A Receptor Sensitivity
Show evidence (3 references)
PMID:9435325 SUPPORT Human Clinical
"In women with premenstrual syndrome, the occurrence of symptoms represents an abnormal response to normal hormonal changes."
The NIMH GnRH-suppression/add-back trial establishes that PMDD symptoms are an abnormal response to normal cyclical hormone changes.
PMID:9435325 SUPPORT Human Clinical
"The 10 women with premenstrual syndrome who were given leuprolide plus estradiol or progesterone had a significant recurrence of symptoms, but no changes in mood occurred in 15 normal women who received the same regimen"
Add-back of estradiol or progesterone reproduced symptoms only in affected individuals, demonstrating differential steroid sensitivity.
PMID:17599809 SUPPORT Human Clinical
"Premenstrual dysphoric disorder (PMDD) is a heritable mood disorder that is triggered by gonadal steroids during the luteal phase in susceptible women."
Confirms the luteal-phase, gonadal-steroid-triggered nature of the disorder in susceptible individuals.
ESC/E(Z) Epigenetic Dysregulation
The strongest molecular lead for the heritable steroid-sensitivity trait is the ESC/E(Z) gene-silencing complex (a PRC2-related chromatin/histone- methylation complex that includes EZH2 and partners). Lymphoblastoid cell lines derived from people with PMDD show intrinsic dysregulation of ESC/E(Z) complex genes, both in untreated (steroid-free) conditions and in their transcriptional response to estradiol and progesterone, providing a cellular correlate of the abnormal hormone sensitivity.
Neuron CL:0000540
Steroid Hormone Receptor Signaling GO:0043401
Downstream
Abnormal Sensitivity to Cyclic Ovarian Steroids
Show evidence (2 references)
PMID:28044059 SUPPORT In Vitro
"over-expression of ESC/E(Z) complex genes (an ovarian steroid-regulated gene silencing complex) in untreated LCLs from women with PMDD"
Demonstrates intrinsic ESC/E(Z) transcriptional dysregulation in patient-derived cells under steroid-free conditions.
PMID:28044059 SUPPORT In Vitro
"These findings demonstrate that LCLs from women with PMDD manifest a cellular difference in ESC/E(Z) complex function both in the untreated condition and in response to ovarian hormones."
Shows the cellular difference persists both at baseline and in the response to ovarian hormones, linking it to differential steroid sensitivity.
Allopregnanolone-GABA-A Receptor Sensitivity
Allopregnanolone (ALLO), a neuroactive metabolite of progesterone, is a potent positive allosteric modulator of the GABA-A receptor, the major inhibitory ionotropic receptor in the brain. In PMDD, the GABA-A receptor's adaptation to the cyclical swing in allopregnanolone is impaired. A rapid decrease in ALLO reduces GABA-A receptor sensitivity and chloride influx, weakening GABAergic inhibition of pyramidal neurons and increasing their excitability, which is proposed to drive the negative-affect symptoms of the disorder.
GABAergic Neuron CL:0000617 Pyramidal Neuron CL:0000598
GABA-A Receptor Signaling GO:0007214 Chloride Transmembrane Transport GO:1902476
GABA-A Receptor (Chloride Channel Complex) GO:0034707
Downstream
Corticolimbic Emotional Dysregulation
Show evidence (2 references)
PMID:36937732 SUPPORT Other
"Premenstrual dysphoric disorder (PMDD) can be conceptualized as a disorder of suboptimal sensitivity to neuroactive steroid hormones."
Frames PMDD as a disorder of suboptimal sensitivity to neuroactive steroids such as allopregnanolone.
PMID:36937732 SUPPORT Other
"A rapid decrease in ALLO reduces the sensitivity of GABAA receptor, and reduces the chloride influx, hindered the inhibitory effect of GABAergic neurons on pyramidal neurons, and then increased the excitability of pyramidal neurons, resulting in PMDD-like behavior."
Provides the mechanistic causal chain from allopregnanolone change through GABA-A/chloride signaling to pyramidal-neuron hyperexcitability.
Corticolimbic Emotional Dysregulation
Functional imaging implicates altered reactivity of corticolimbic emotion circuitry (notably the amygdala) across the menstrual cycle in PMDD. The relationship is complex rather than a simple luteal increase: amygdala reactivity in affected individuals is modulated by trait anxiety and by progesterone levels, consistent with a role for emotional-regulation circuitry downstream of the neurosteroid-GABA-A mechanism.
Neuron CL:0000540
Steroid Hormone Receptor Signaling GO:0043401
Amygdala UBERON:0001876 Dorsolateral Prefrontal Cortex UBERON:0009834
Show evidence (2 references)
PMID:22814368 PARTIAL Human Clinical
"while the study failed to indicate increased luteal phase amygdala reactivity in women with PMDD, our findings suggest that anxiety proneness and progesterone levels modulate menstrual cycle related amygdala reactivity in women with PMDD"
Supports amygdala involvement modulated by progesterone and trait anxiety, while explicitly refuting a simple luteal-phase increase in reactivity (hence PARTIAL).
PMID:29145910 SUPPORT Human Clinical
"during the late luteal phase, women with PMDD had hypoactivation in right dorsolateral prefrontal cortex (dlPFC) during all conditions of the emotion-regulation task"
fMRI shows luteal-phase right dlPFC hypoactivation during emotion regulation, providing the impaired top-down prefrontal control side of the corticolimbic dysregulation.
Serotonergic Involvement
Serotonergic neurotransmission is implicated by the distinctive treatment response of PMDD: symptoms respond preferentially to serotonin reuptake inhibitors over noradrenergic agents, and the response occurs within days rather than the weeks required in major depression. The rapid, luteal-phase efficacy suggests a mechanism partly distinct from monoamine theories of depression, plausibly involving serotonergic modulation of neurosteroid synthesis.
Serotonergic Neuron CL:0000850
Serotonin Signaling GO:0007210
Downstream
Allopregnanolone-GABA-A Receptor Sensitivity
Show evidence (1 reference)
PMID:22764360 SUPPORT Human Clinical
"symptom response is better with serotonin reuptake inhibitors (SRIs) than with noradrenergic agents"
The preferential response to serotonergic over noradrenergic agents supports a serotonergic component to the pathophysiology.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Premenstrual Dysphoric Disorder Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Digestive 1
Bloating FREQUENT Abdominal distention HP:0003270
Temporal: RECURRENT
Sensation of bloating or weight gain; a physical symptom criterion.
Show evidence (1 reference)
PMID:22764360 SUPPORT Human Clinical
"physical symptoms such as bloating and breast tenderness are both unique and among the most frequently reported premenstrual symptoms in women suffering from premenstrual dysphoric disorder"
Lists bloating among the most frequently reported physical symptoms.
Nervous System 9
Irritability VERY_FREQUENT Irritability HP:0000737
Temporal: RECURRENT
Irritability, anger, or increased interpersonal conflict; a core DSM-5 symptom and the most distinguishing feature of PMDD.
Show evidence (1 reference)
PMID:22764360 SUPPORT Human Clinical
"the psychological symptoms most commonly reported by women with significant premenstrual distress are mood lability and irritability"
Confirms irritability as a most-commonly-reported core symptom.
Depressed Mood FREQUENT Depression HP:0000716
Temporal: RECURRENT
Markedly depressed mood, feelings of hopelessness, or self-deprecating thoughts; a core DSM-5 symptom.
Anhedonia FREQUENT Anhedonia HP:0012154
Temporal: RECURRENT
Markedly decreased interest in usual activities; DSM-5 symptom B5.
Show evidence (1 reference)
PMID:35884622 SUPPORT Human Clinical
"the importance of apathy (i.e., low interest) on the expression of behavioral symptomatology"
Prospective daily-rating data highlight apathy/low interest (decreased interest in activities) as a premenstrual behavioral symptom.
Anxiety FREQUENT Anxiety HP:0000739
Temporal: RECURRENT
Anxiety, tension, or feeling keyed up or on edge; a core DSM-5 symptom.
Show evidence (1 reference)
PMID:39952094 SUPPORT Other
"Symptoms include mood swings, irritability, anxiety, fatigue, physical discomfort, and disruptions to sleep and circadian rhythms, such as altered melatonin secretion."
A PMDD review lists anxiety among the characteristic luteal-phase symptoms.
Difficulty Concentrating FREQUENT Cognitive impairment HP:0100543
Temporal: RECURRENT
Show evidence (1 reference)
PMID:41239306 SUPPORT Human Clinical
"PMDD individuals exhibited the most considerable cognitive shifts"
Cognitive performance shifted most across the menstrual cycle in the PMDD group, supporting luteal-phase concentration/cognitive difficulty.
Appetite Change and Food Cravings FREQUENT Polyphagia HP:0002591
Temporal: RECURRENT
Marked change in appetite, overeating, or specific food cravings.
Show evidence (1 reference)
PMID:35884622 SUPPORT Human Clinical
"Low interest was associated with a premenstrual increase in insomnia (p ≤ 0.05) and appetite/eating (p ≤ 0.05)."
Prospective daily ratings link the premenstrual phase to increased appetite/eating behavior.
Sleep Disturbance FREQUENT Sleep disturbance HP:0002360
Temporal: RECURRENT
Hypersomnia or insomnia.
Show evidence (1 reference)
PMID:35884622 SUPPORT Human Clinical
"Sleep and eating behaviors are disturbed during the premenstrual phase of the menstrual cycle in a significant number of reproductive-age women."
Documents premenstrual disturbance of sleep behavior; the study further links premenstrual insomnia to occupational, recreational, and relational impairment.
Headache OCCASIONAL Headache HP:0002315
Temporal: RECURRENT
Show evidence (1 reference)
PMID:42293072 PARTIAL Human Clinical
"the presence of PMDD was associated with an increase of 3.113 points in HIT-6 scores"
Among people with menstrual migraine, a PMDD diagnosis was associated with greater headache impact; PARTIAL because this is a migraine-enriched population rather than direct evidence that headache is a general PMDD symptom.
Suicidal Ideation OCCASIONAL Suicidal ideation HP:0031589
Temporal: RECURRENT
Luteal-phase suicidal ideation is markedly elevated and is a critical safety concern even though PMDD is not directly lethal.
Show evidence (1 reference)
PMID:39397675 SUPPORT Human Clinical
"Greater lifetime stressor exposure predicted a more pronounced perimenstrual increase in active SI"
In a sample with past-month suicidal ideation, perimenstrual worsening of active suicidal ideation tracked with cumulative stressor exposure, supporting elevated luteal-phase suicidality.
Constitutional 1
Fatigue FREQUENT Fatigue HP:0012378
Temporal: RECURRENT
Lethargy, easy fatigability, or marked lack of energy.
Show evidence (1 reference)
PMID:39952094 SUPPORT Other
"Symptoms include mood swings, irritability, anxiety, fatigue, physical discomfort, and disruptions to sleep and circadian rhythms, such as altered melatonin secretion."
A PMDD review lists fatigue among the characteristic luteal-phase symptoms.
Other 2
Affective Lability VERY_FREQUENT Emotional lability HP:0000712
Temporal: RECURRENT
Mood swings, sudden sadness or tearfulness, rejection sensitivity; a core DSM-5 symptom.
Show evidence (1 reference)
PMID:22764360 SUPPORT Human Clinical
"the psychological symptoms most commonly reported by women with significant premenstrual distress are mood lability and irritability"
Identifies mood lability as one of the most commonly reported and characteristic symptoms.
Breast Tenderness FREQUENT Mastalgia HP:0034265
Temporal: RECURRENT
Breast tenderness or swelling; a physical symptom criterion.
Show evidence (1 reference)
PMID:22764360 SUPPORT Human Clinical
"physical symptoms such as bloating and breast tenderness are both unique and among the most frequently reported premenstrual symptoms in women suffering from premenstrual dysphoric disorder"
Lists breast tenderness among the most frequently reported and characteristic physical symptoms.
🧬

Genetic Associations

4
ESR1 (Risk Factor)
Gene: ESR1 hgnc:3467
Show evidence (1 reference)
PMID:17599809 SUPPORT Human Clinical
"Four SNPs in intron 4 of ESR1 showed significantly different genotype and allele distributions between patients and control subjects."
Direct case-control association of ESR1 intron-4 variants with PMDD risk.
COMT (Modifier)
Gene: COMT hgnc:2228
Show evidence (1 reference)
PMID:17599809 SUPPORT Human Clinical
"the significant associations with ESR1 were observed only in those with the Val/Val genotype"
COMT Val/Val genotype modifies the ESR1 risk association.
EZH2 (Risk Factor)
Gene: EZH2 hgnc:3527
Show evidence (1 reference)
PMID:28044059 PARTIAL In Vitro
"Dysregulation of ESC/E(Z) complex function could contribute to PMDD."
Implicates the ESC/E(Z) complex (which includes EZH2) in PMDD; PARTIAL because no specific EZH2 risk variant is established.
BDNF (Risk Factor)
Gene: BDNF hgnc:1033
Show evidence (1 reference)
PMID:30356121 SUPPORT Model Organism
"we show that E2 add-back induces anxiety-like and depression-like behavior in Het-Met mice, but not in WT mice"
A BDNF Val66Met (Met) knock-in mouse develops anxiety- and depression-like behavior on estradiol add-back, recapitulating the estradiol-dependent PMDD-like phenotype; the same study found shared ESC/E(Z) epigenetic biomarkers across mouse and human PMDD cells.
💊

Medical Actions

5
Selective Serotonin Reuptake Inhibitors (SSRIs)
Action: Pharmacotherapy NCIT:C15986
Agent: fluoxetine CHEBI:5118 sertraline CHEBI:9123
First-line pharmacotherapy. SSRIs (e.g., fluoxetine, sertraline, paroxetine) are effective given continuously or limited to the luteal phase, and act within days in PMDD rather than the weeks needed in depression. Intermittent luteal-phase dosing performs comparably to continuous dosing and avoids antidepressant withdrawal.
Mechanism Target:
MODULATES Serotonergic Involvement — SSRIs enhance serotonergic neurotransmission, the rapid-onset luteal-phase mechanism implicated in PMDD.
Show evidence (3 references)
PMID:39140320 SUPPORT Human Clinical
"Selective serotonin reuptake inhibitors (SSRIs) are increasingly used as a treatment for PMS and PMDD, either administered in the luteal phase or continuously."
Confirms SSRIs as a treatment given either luteally or continuously.
PMID:35686687 SUPPORT Human Clinical
"Intermittent (luteal phase) dosing of selective serotonin reuptake inhibitors is one treatment strategy for premenstrual syndromes such as premenstrual dysphoric disorder. This avoids the risk of the antidepressant withdrawal syndrome associated with long-term continuous dosing."
Supports intermittent luteal-phase SSRI dosing and its advantage of avoiding withdrawal.
PMID:22764360 SUPPORT Human Clinical
"SRI treatment limited to the luteal phase appears to be as effective as daily administration"
Supports comparable efficacy of luteal-only versus daily SSRI dosing.
Drospirenone-Containing Combined Oral Contraceptive
Action: Pharmacotherapy NCIT:C15986
Agent: drospirenone CHEBI:50838
A combined oral contraceptive containing drospirenone with a low ethinyl- estradiol dose (24/4 regimen) is approved for PMDD and suppresses the cyclical ovarian-steroid fluctuation. Evidence is of low-to-moderate quality with a substantial placebo effect.
Mechanism Target:
INHIBITS Abnormal Sensitivity to Cyclic Ovarian Steroids — By suppressing ovulation, the drospirenone combined oral contraceptive flattens the cyclical ovarian-steroid fluctuation that triggers symptoms in susceptible individuals.
Show evidence (2 references)
PMID:37365881 SUPPORT Human Clinical
"A combined oral contraceptive containing drospirenone and a low oestrogen dose has been approved for treating PMDD in women who choose combined oral contraceptives for contraception."
Confirms approval of a drospirenone-containing COC for PMDD.
PMID:37365881 PARTIAL Human Clinical
"COCs containing drospirenone and EE may improve premenstrual symptoms that result in functional impairments in women with PMDD."
Supports symptom improvement; PARTIAL given the low-quality evidence and large placebo effect noted in the review.
GnRH Agonist with Hormone Add-Back
Action: Pharmacotherapy NCIT:C15986
Agent: leuprolide CHEBI:6427
For severe or refractory PMDD, gonadotropin-releasing hormone agonists induce medical ovarian suppression and are effective for behavioral and physical symptoms; hormone add-back is needed to offset the adverse effects of hypogonadism, though add-back can transiently reintroduce negative mood in some patients.
Mechanism Target:
INHIBITS Abnormal Sensitivity to Cyclic Ovarian Steroids — GnRH agonists abolish cyclical ovarian-steroid production, removing the hormonal trigger to which susceptible individuals are abnormally sensitive; this is the basis of the diagnostic GnRH-suppression paradigm.
Show evidence (1 reference)
PMID:22764360 SUPPORT Human Clinical
"While GnRH agonist treatment appears to be effective for both the behavioral and physical symptoms of premenstrual syndrome/premenstrual dysphoric disorder in the majority of cases, hormone add-back is required to reduce the adverse sequelae of long-term hypogonadism."
Supports GnRH agonist efficacy and the need for hormone add-back.
Cognitive Behavioral Therapy
Action: cognitive behavioral therapy Ontology label: cognitive and behavioral intervention MAXO:0000010
Evidence-based psychotherapy used as a non-pharmacological option or adjunct, targeting coping and symptom management across the cycle.
Show evidence (2 references)
PMID:31078196 SUPPORT Human Clinical
"Second-line treatments include oral contraceptives containing drospirenone, other ovulation suppression methods, calcium, chasteberry, and cognitive-behavioral therapy."
A clinical review lists cognitive-behavioral therapy among the second-line treatment options for PMDD.
PMID:19247573 PARTIAL Human Clinical
"Our review revealed a dearth of evidence providing statistically significant CBT intervention effects."
A systematic review found only limited evidence for CBT efficacy in PMS/PMDD, so support for CBT is partial.
Bright Light Therapy
Action: bright white light therapy Ontology label: Bright White Light Therapy NCIT:C174524
Luteal-phase bright white light therapy (as used for seasonal affective disorder) reduced luteal depression and premenstrual tension versus a dim-light placebo in a small double-blind crossover trial in late luteal phase dysphoric disorder (the historical name for PMDD). Evidence is limited by small sample size.
Show evidence (1 reference)
PMID:10482337 SUPPORT Human Clinical
"the active bright white light condition significantly reduced depression and pre-menstrual tension scores during the symptomatic luteal phase, compared to baseline, while the placebo dim red light condition did not"
A double-blind crossover trial found bright white light therapy reduced luteal depression and premenstrual tension versus dim-light placebo in late luteal phase dysphoric disorder (PMDD).
🌍

Environmental Factors

2
History of Interpersonal Trauma
Interpersonal trauma and childhood adversity are associated with onset or expression of PMDD.
Show evidence (1 reference)
PMID:22764360 SUPPORT Human Clinical
"A history of interpersonal trauma"
Identifies interpersonal trauma as a factor influencing onset or expression of PMDD.
Chronic Stress
Perceived stress is greater in the luteal phase in affected individuals and may modify symptom expression.
Show evidence (2 references)
PMID:22764360 SUPPORT Human Clinical
"Perception of the frequency and severity of stress has been reported to be greater during the luteal but not the follicular phase of the menstrual cycle in women with prospectively confirmed premenstrual dysphoric disorder"
Documents heightened luteal-phase stress perception in PMDD.
PMID:39397675 SUPPORT Human Clinical
"greater lifetime stressor exposure may lead to heightened emotional reactivity to ovarian hormone fluctuations, elevating the risk of psychopathology"
Prospective evidence that cumulative lifetime stressor exposure heightens emotional reactivity to ovarian-hormone fluctuation, supporting stress as a gene-by-environment modifier of PMDD-like symptom severity.
🔬

Biochemical Markers

1
Allopregnanolone (Altered sensitivity)
Context: Neuroactive progesterone metabolite and GABA-A receptor modulator; in PMDD the response to its normal cyclical fluctuation is abnormal rather than its absolute level.
Show evidence (1 reference)
PMID:36937732 SUPPORT Other
"PMDD pathophysiology is rooted in GABAA receptor sensitivity changes caused by rapid changes in ALLO levels."
Identifies altered GABA-A sensitivity to allopregnanolone changes as the root of PMDD pathophysiology.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Premenstrual Dysphoric Disorder:

Premenstrual Exacerbation (PME) of an Underlying Disorder
Overlapping Features Premenstrual worsening of an underlying mood, anxiety, or personality disorder (e.g., major depression, bipolar disorder, generalized anxiety). Unlike PMDD, symptoms persist through the follicular phase rather than fully remitting after menses; this is the key discriminator and the reason prospective charting is required.
Distinguishing Features
  • In PMDD symptoms remit after menses and the follicular phase is symptom-free; in PME the underlying disorder persists across the whole cycle.
Show evidence (1 reference)
PMID:22764360 SUPPORT Human Clinical
"the pattern of predictable symptom onset and offset with phases of the menstrual cycle remains a key feature distinguishing premenstrual dysphoric disorder from other cyclic mood disorders"
Identifies the predictable onset/offset pattern as the distinguishing feature from other cyclic mood disorders.
Premenstrual Syndrome (PMS)
Overlapping Features A milder and more prevalent condition with fewer and less severe affective symptoms that does not meet the DSM-5 threshold for PMDD. PMDD lies at the severe end of the same continuum of premenstrual symptoms.
Distinguishing Features
  • PMS is milder, with fewer core affective symptoms and less functional impairment than PMDD.
Show evidence (1 reference)
PMID:31078196 SUPPORT Human Clinical
"Premenstrual dysphoric disorder (PMDD) comprises emotional and physical symptoms and functional impairment that lie on the severe end of the continuum of premenstrual symptoms."
Positions PMDD at the severe end of the premenstrual-symptom continuum, distinguishing it from milder PMS.
Bipolar Disorder
Overlapping Features People with bipolar disorder frequently experience premenstrual mood worsening, which can be confused with or co-occur with PMDD. Distinguishing the two is clinically important because the first-line PMDD treatment (SSRIs) can provoke treatment-emergent manic symptoms in bipolar disorder.
Distinguishing Features
  • Bipolar mood episodes are not confined to the luteal phase and do not fully remit after menses, unlike PMDD.
  • SSRIs, first-line for PMDD, carry a risk of treatment-emergent mania in bipolar disorder, so the distinction changes management.
Show evidence (2 references)
PMID:34512419 SUPPORT Human Clinical
"a substantial percentage of females with BD experience premenstrual mood worsening of varying degrees of severity"
Establishes that premenstrual mood worsening is common in bipolar disorder, creating diagnostic overlap with PMDD.
PMID:34512419 SUPPORT Human Clinical
"the first line treatment of PMDD in the general population is selective serotonin reuptake inhibitors, which produce risk of treatment-emergent manic symptoms"
Supports a management-relevant distinction whereby SSRIs used for PMDD risk inducing mania in bipolar disorder.
🔬

Clinical Trials

1
NCT03697265 PHASE_II COMPLETED
Phase IIb randomised, double-blind, placebo-controlled trial of sepranolone (UC1010), an endogenous neurosteroid that antagonizes allopregnanolone's action at the GABA-A receptor, dosed during the two weeks before menstruation across three cycles in PMDD. Directly tests the allopregnanolone-GABA-A pathophysiology.
Target Phenotypes: Irritability HP:0000737 Emotional Lability HP:0000712
Show evidence (1 reference)
clinicaltrials:NCT03697265 SUPPORT Human Clinical
"The objective of this phase IIb study is to evaluate the effect and safety of Sepranolone (UC1010) on premenstrual symptoms in women with Premenstrual Dysphoric Disorder (PMDD)."
Documents a mechanism-targeted neurosteroid trial in PMDD aimed at the allopregnanolone-GABA-A axis.
{ }

Source YAML

click to show 
name: Premenstrual Dysphoric Disorder
creation_date: "2026-06-24T00:00:00Z"
category: Complex
description: >
  Premenstrual dysphoric disorder (PMDD) is a severe, cyclical mood disorder in
  which clinically significant affective and somatic symptoms emerge during the
  luteal phase of the menstrual cycle (roughly the week before menstruation),
  remit within a few days of the onset of bleeding, and are essentially absent in
  the follicular phase. PMDD is not a state of abnormal circulating hormone
  levels: estradiol and progesterone cycle normally. Instead it reflects an
  abnormal central nervous system sensitivity to the normal cyclical fluctuation
  of ovarian steroids, so the trigger is a physiological hormonal change that
  unaffected people tolerate without mood disturbance. It was added as a distinct
  diagnostic category in the depressive disorders section of DSM-5 (2013) and is
  diagnosed by prospective daily symptom ratings across at least two cycles
  rather than by any biomarker or imaging test. PMDD affects people with
  ovulatory menstrual cycles during their reproductive years.
parents:
- Psychiatric Disease
- Mood Disorder
synonyms:
- PMDD
- Late luteal phase dysphoric disorder
- Severe premenstrual syndrome
disease_term:
  preferred_term: premenstrual dysphoric disorder
  term:
    id: MONDO:1010182
    label: premenstrual dysphoric disorder
pathophysiology:
- name: Abnormal Sensitivity to Cyclic Ovarian Steroids
  description: >
    The proximate cause of PMDD is an abnormal central nervous system response to
    the normal luteal-phase fluctuation of ovarian steroids, not abnormal hormone
    levels. In the landmark NIMH experiment, suppressing ovarian function with the
    GnRH agonist leuprolide abolished symptoms in affected individuals, and adding
    back estradiol or progesterone reintroduced them, whereas unaffected
    individuals showed no mood change to the identical manipulation. This
    differential sensitivity is the unifying mechanistic frame for the disorder.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Response to Progesterone
    term:
      id: GO:0032570
      label: response to progesterone
  - preferred_term: Steroid Hormone Receptor Signaling
    term:
      id: GO:0043401
      label: steroid hormone receptor signaling pathway
  downstream:
  - target: Allopregnanolone-GABA-A Receptor Sensitivity
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - The normal luteal rise and fall of progesterone changes brain levels of the
      neuroactive metabolite allopregnanolone, which acts on the GABA-A receptor.
  evidence:
  - reference: PMID:9435325
    reference_title: "Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In women with premenstrual syndrome, the occurrence of symptoms
      represents an abnormal response to normal hormonal changes."
    explanation: The NIMH GnRH-suppression/add-back trial establishes that PMDD
      symptoms are an abnormal response to normal cyclical hormone changes.
  - reference: PMID:9435325
    reference_title: "Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The 10 women with premenstrual syndrome who were given leuprolide
      plus estradiol or progesterone had a significant recurrence of symptoms, but
      no changes in mood occurred in 15 normal women who received the same regimen"
    explanation: Add-back of estradiol or progesterone reproduced symptoms only in
      affected individuals, demonstrating differential steroid sensitivity.
  - reference: PMID:17599809
    reference_title: "Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Premenstrual dysphoric disorder (PMDD) is a heritable mood disorder
      that is triggered by gonadal steroids during the luteal phase in susceptible
      women."
    explanation: Confirms the luteal-phase, gonadal-steroid-triggered nature of
      the disorder in susceptible individuals.
- name: ESC/E(Z) Epigenetic Dysregulation
  description: >
    The strongest molecular lead for the heritable steroid-sensitivity trait is
    the ESC/E(Z) gene-silencing complex (a PRC2-related chromatin/histone-
    methylation complex that includes EZH2 and partners). Lymphoblastoid cell
    lines derived from people with PMDD show intrinsic dysregulation of ESC/E(Z)
    complex genes, both in untreated (steroid-free) conditions and in their
    transcriptional response to estradiol and progesterone, providing a cellular
    correlate of the abnormal hormone sensitivity.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Steroid Hormone Receptor Signaling
    term:
      id: GO:0043401
      label: steroid hormone receptor signaling pathway
  downstream:
  - target: Abnormal Sensitivity to Cyclic Ovarian Steroids
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Intrinsic ESC/E(Z) transcriptional dysregulation is proposed to set the
      abnormal cellular response to ovarian steroids, though the path from
      lymphoblastoid-cell findings to brain mood circuitry is not established.
  evidence:
  - reference: PMID:28044059
    reference_title: "The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "over-expression of ESC/E(Z) complex genes (an ovarian
      steroid-regulated gene silencing complex) in untreated LCLs from women with
      PMDD"
    explanation: Demonstrates intrinsic ESC/E(Z) transcriptional dysregulation in
      patient-derived cells under steroid-free conditions.
  - reference: PMID:28044059
    reference_title: "The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These findings demonstrate that LCLs from women with PMDD manifest a
      cellular difference in ESC/E(Z) complex function both in the untreated
      condition and in response to ovarian hormones."
    explanation: Shows the cellular difference persists both at baseline and in the
      response to ovarian hormones, linking it to differential steroid sensitivity.
- name: Allopregnanolone-GABA-A Receptor Sensitivity
  description: >
    Allopregnanolone (ALLO), a neuroactive metabolite of progesterone, is a potent
    positive allosteric modulator of the GABA-A receptor, the major inhibitory
    ionotropic receptor in the brain. In PMDD, the GABA-A receptor's adaptation to
    the cyclical swing in allopregnanolone is impaired. A rapid decrease in ALLO
    reduces GABA-A receptor sensitivity and chloride influx, weakening GABAergic
    inhibition of pyramidal neurons and increasing their excitability, which is
    proposed to drive the negative-affect symptoms of the disorder.
  cell_types:
  - preferred_term: GABAergic Neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  - preferred_term: Pyramidal Neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
  biological_processes:
  - preferred_term: GABA-A Receptor Signaling
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
  - preferred_term: Chloride Transmembrane Transport
    term:
      id: GO:1902476
      label: chloride transmembrane transport
  cellular_components:
  - preferred_term: GABA-A Receptor (Chloride Channel Complex)
    term:
      id: GO:0034707
      label: chloride channel complex
  downstream:
  - target: Corticolimbic Emotional Dysregulation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced GABAergic inhibition increases excitability of corticolimbic
      pyramidal neurons, impairing emotional regulation.
  evidence:
  - reference: PMID:36937732
    reference_title: "Role of allopregnanolone-mediated gamma-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Premenstrual dysphoric disorder (PMDD) can be conceptualized as a
      disorder of suboptimal sensitivity to neuroactive steroid hormones."
    explanation: Frames PMDD as a disorder of suboptimal sensitivity to neuroactive
      steroids such as allopregnanolone.
  - reference: PMID:36937732
    reference_title: "Role of allopregnanolone-mediated gamma-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rapid decrease in ALLO reduces the sensitivity of GABAA receptor,
      and reduces the chloride influx, hindered the inhibitory effect of GABAergic
      neurons on pyramidal neurons, and then increased the excitability of
      pyramidal neurons, resulting in PMDD-like behavior."
    explanation: Provides the mechanistic causal chain from allopregnanolone change
      through GABA-A/chloride signaling to pyramidal-neuron hyperexcitability.
- name: Corticolimbic Emotional Dysregulation
  description: >
    Functional imaging implicates altered reactivity of corticolimbic emotion
    circuitry (notably the amygdala) across the menstrual cycle in PMDD. The
    relationship is complex rather than a simple luteal increase: amygdala
    reactivity in affected individuals is modulated by trait anxiety and by
    progesterone levels, consistent with a role for emotional-regulation circuitry
    downstream of the neurosteroid-GABA-A mechanism.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Steroid Hormone Receptor Signaling
    term:
      id: GO:0043401
      label: steroid hormone receptor signaling pathway
  locations:
  - preferred_term: Amygdala
    term:
      id: UBERON:0001876
      label: amygdala
  - preferred_term: Dorsolateral Prefrontal Cortex
    term:
      id: UBERON:0009834
      label: dorsolateral prefrontal cortex
  evidence:
  - reference: PMID:22814368
    reference_title: "Menstrual cycle effects on amygdala reactivity to emotional stimulation in premenstrual dysphoric disorder."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "while the study failed to indicate increased luteal phase amygdala
      reactivity in women with PMDD, our findings suggest that anxiety proneness and
      progesterone levels modulate menstrual cycle related amygdala reactivity in
      women with PMDD"
    explanation: Supports amygdala involvement modulated by progesterone and trait
      anxiety, while explicitly refuting a simple luteal-phase increase in
      reactivity (hence PARTIAL).
  - reference: PMID:29145910
    reference_title: "Brain activation during emotion regulation in women with premenstrual dysphoric disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "during the late luteal phase, women with PMDD had hypoactivation in
      right dorsolateral prefrontal cortex (dlPFC) during all conditions of the
      emotion-regulation task"
    explanation: fMRI shows luteal-phase right dlPFC hypoactivation during emotion
      regulation, providing the impaired top-down prefrontal control side of the
      corticolimbic dysregulation.
- name: Serotonergic Involvement
  description: >
    Serotonergic neurotransmission is implicated by the distinctive treatment
    response of PMDD: symptoms respond preferentially to serotonin reuptake
    inhibitors over noradrenergic agents, and the response occurs within days
    rather than the weeks required in major depression. The rapid, luteal-phase
    efficacy suggests a mechanism partly distinct from monoamine theories of
    depression, plausibly involving serotonergic modulation of neurosteroid
    synthesis.
  cell_types:
  - preferred_term: Serotonergic Neuron
    term:
      id: CL:0000850
      label: serotonergic neuron
  biological_processes:
  - preferred_term: Serotonin Signaling
    term:
      id: GO:0007210
      label: serotonin receptor signaling pathway
  downstream:
  - target: Allopregnanolone-GABA-A Receptor Sensitivity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Serotonergic tone is proposed to modulate neurosteroid (allopregnanolone)
      synthesis via 3-alpha-hydroxysteroid dehydrogenase, which would feed the
      GABA-A receptor mechanism; this links the rapid SSRI response to the
      neurosteroid axis but the intermediates are not fully established.
  evidence:
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "symptom response is better with serotonin reuptake inhibitors (SRIs)
      than with noradrenergic agents"
    explanation: The preferential response to serotonergic over noradrenergic
      agents supports a serotonergic component to the pathophysiology.
phenotypes:
- name: Affective Lability
  category: Psychiatric
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Mood swings, sudden sadness or tearfulness, rejection sensitivity; a core
    DSM-5 symptom.
  phenotype_term:
    preferred_term: Emotional Lability
    term:
      id: HP:0000712
      label: Emotional lability
    temporality: RECURRENT
  evidence:
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the psychological symptoms most commonly reported by women with
      significant premenstrual distress are mood lability and irritability"
    explanation: Identifies mood lability as one of the most commonly reported and
      characteristic symptoms.
- name: Irritability
  category: Psychiatric
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Irritability, anger, or increased interpersonal conflict; a core DSM-5
    symptom and the most distinguishing feature of PMDD.
  phenotype_term:
    preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
    temporality: RECURRENT
  evidence:
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the psychological symptoms most commonly reported by women with
      significant premenstrual distress are mood lability and irritability"
    explanation: Confirms irritability as a most-commonly-reported core symptom.
- name: Depressed Mood
  category: Psychiatric
  frequency: FREQUENT
  diagnostic: true
  notes: Markedly depressed mood, feelings of hopelessness, or self-deprecating
    thoughts; a core DSM-5 symptom.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
    temporality: RECURRENT
- name: Anhedonia
  category: Psychiatric
  frequency: FREQUENT
  diagnostic: true
  notes: Markedly decreased interest in usual activities; DSM-5 symptom B5.
  phenotype_term:
    preferred_term: Anhedonia
    term:
      id: HP:0012154
      label: Anhedonia
    temporality: RECURRENT
  evidence:
  - reference: PMID:35884622
    reference_title: "Behavioral Symptomatology in the Premenstruum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the importance of apathy (i.e., low interest) on the expression of
      behavioral symptomatology"
    explanation: Prospective daily-rating data highlight apathy/low interest
      (decreased interest in activities) as a premenstrual behavioral symptom.
- name: Anxiety
  category: Psychiatric
  frequency: FREQUENT
  diagnostic: true
  notes: Anxiety, tension, or feeling keyed up or on edge; a core DSM-5 symptom.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
    temporality: RECURRENT
  evidence:
  - reference: PMID:39952094
    reference_title: "The impact of pharmacotherapy for premenstrual dysphoric disorder on sleep."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Symptoms include mood swings, irritability, anxiety, fatigue,
      physical discomfort, and disruptions to sleep and circadian rhythms, such as
      altered melatonin secretion."
    explanation: A PMDD review lists anxiety among the characteristic luteal-phase
      symptoms.
- name: Difficulty Concentrating
  category: Cognitive
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cognitive Impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
    temporality: RECURRENT
  evidence:
  - reference: PMID:41239306
    reference_title: "Pre and Post Menstruation Cognitive Functioning in Women with Premenstrual Dysphoric Disorder, Premenstrual Syndrome and Controls: A Quasi Experimental Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PMDD individuals exhibited the most considerable cognitive shifts"
    explanation: Cognitive performance shifted most across the menstrual cycle in
      the PMDD group, supporting luteal-phase concentration/cognitive difficulty.
- name: Fatigue
  category: Constitutional
  frequency: FREQUENT
  notes: Lethargy, easy fatigability, or marked lack of energy.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
    temporality: RECURRENT
  evidence:
  - reference: PMID:39952094
    reference_title: "The impact of pharmacotherapy for premenstrual dysphoric disorder on sleep."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Symptoms include mood swings, irritability, anxiety, fatigue,
      physical discomfort, and disruptions to sleep and circadian rhythms, such as
      altered melatonin secretion."
    explanation: A PMDD review lists fatigue among the characteristic luteal-phase
      symptoms.
- name: Appetite Change and Food Cravings
  category: Constitutional
  frequency: FREQUENT
  notes: Marked change in appetite, overeating, or specific food cravings.
  phenotype_term:
    preferred_term: Polyphagia
    term:
      id: HP:0002591
      label: Polyphagia
    temporality: RECURRENT
  evidence:
  - reference: PMID:35884622
    reference_title: "Behavioral Symptomatology in the Premenstruum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Low interest was associated with a premenstrual increase in insomnia
      (p ≤ 0.05) and appetite/eating (p ≤ 0.05)."
    explanation: Prospective daily ratings link the premenstrual phase to increased
      appetite/eating behavior.
- name: Sleep Disturbance
  category: Sleep
  frequency: FREQUENT
  notes: Hypersomnia or insomnia.
  phenotype_term:
    preferred_term: Sleep Disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
    temporality: RECURRENT
  evidence:
  - reference: PMID:35884622
    reference_title: "Behavioral Symptomatology in the Premenstruum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sleep and eating behaviors are disturbed during the premenstrual
      phase of the menstrual cycle in a significant number of reproductive-age
      women."
    explanation: Documents premenstrual disturbance of sleep behavior; the study
      further links premenstrual insomnia to occupational, recreational, and
      relational impairment.
- name: Breast Tenderness
  category: Other
  frequency: FREQUENT
  notes: Breast tenderness or swelling; a physical symptom criterion.
  phenotype_term:
    preferred_term: Mastalgia
    term:
      id: HP:0034265
      label: Mastalgia
    temporality: RECURRENT
  evidence:
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "physical symptoms such as bloating and breast tenderness are both
      unique and among the most frequently reported premenstrual symptoms in women
      suffering from premenstrual dysphoric disorder"
    explanation: Lists breast tenderness among the most frequently reported and
      characteristic physical symptoms.
- name: Bloating
  category: Other
  frequency: FREQUENT
  notes: Sensation of bloating or weight gain; a physical symptom criterion.
  phenotype_term:
    preferred_term: Abdominal Distention
    term:
      id: HP:0003270
      label: Abdominal distention
    temporality: RECURRENT
  evidence:
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "physical symptoms such as bloating and breast tenderness are both
      unique and among the most frequently reported premenstrual symptoms in women
      suffering from premenstrual dysphoric disorder"
    explanation: Lists bloating among the most frequently reported physical
      symptoms.
- name: Headache
  category: Neurological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
    temporality: RECURRENT
  evidence:
  - reference: PMID:42293072
    reference_title: "Premenstrual syndrome, premenstrual dysphoric disorder, and coping strategies in women with menstrual migraine."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "the presence of PMDD was associated with an increase of 3.113 points
      in HIT-6 scores"
    explanation: Among people with menstrual migraine, a PMDD diagnosis was
      associated with greater headache impact; PARTIAL because this is a
      migraine-enriched population rather than direct evidence that headache is a
      general PMDD symptom.
- name: Suicidal Ideation
  category: Psychiatric
  frequency: OCCASIONAL
  notes: Luteal-phase suicidal ideation is markedly elevated and is a critical
    safety concern even though PMDD is not directly lethal.
  phenotype_term:
    preferred_term: Suicidal Ideation
    term:
      id: HP:0031589
      label: Suicidal ideation
    temporality: RECURRENT
  evidence:
  - reference: PMID:39397675
    reference_title: "Cumulative stressor exposure predicts menstrual cycle affective changes in a transdiagnostic outpatient sample with past-month suicidal ideation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Greater lifetime stressor exposure predicted a more pronounced
      perimenstrual increase in active SI"
    explanation: In a sample with past-month suicidal ideation, perimenstrual
      worsening of active suicidal ideation tracked with cumulative stressor
      exposure, supporting elevated luteal-phase suicidality.
biochemical:
- name: Allopregnanolone
  presence: Altered sensitivity
  context: Neuroactive progesterone metabolite and GABA-A receptor modulator; in
    PMDD the response to its normal cyclical fluctuation is abnormal rather than
    its absolute level.
  evidence:
  - reference: PMID:36937732
    reference_title: "Role of allopregnanolone-mediated gamma-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PMDD pathophysiology is rooted in GABAA receptor sensitivity changes
      caused by rapid changes in ALLO levels."
    explanation: Identifies altered GABA-A sensitivity to allopregnanolone changes
      as the root of PMDD pathophysiology.
genetic:
- name: ESR1
  gene_term:
    preferred_term: ESR1
    term:
      id: hgnc:3467
      label: ESR1
  association: Risk Factor
  notes: Estrogen receptor alpha gene; intron-4 SNPs differ between cases and
    controls.
  evidence:
  - reference: PMID:17599809
    reference_title: "Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four SNPs in intron 4 of ESR1 showed significantly different genotype
      and allele distributions between patients and control subjects."
    explanation: Direct case-control association of ESR1 intron-4 variants with
      PMDD risk.
- name: COMT
  gene_term:
    preferred_term: COMT
    term:
      id: hgnc:2228
      label: COMT
  association: Modifier
  notes: Catechol-O-methyltransferase Val158Met; the ESR1 association was seen only
    in Val/Val carriers, suggesting COMT modifies the estrogen-receptor effect.
  evidence:
  - reference: PMID:17599809
    reference_title: "Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the significant associations with ESR1 were observed only in those
      with the Val/Val genotype"
    explanation: COMT Val/Val genotype modifies the ESR1 risk association.
- name: EZH2
  gene_term:
    preferred_term: EZH2
    term:
      id: hgnc:3527
      label: EZH2
  association: Risk Factor
  notes: Core member of the ESC/E(Z) gene-silencing complex shown to be
    intrinsically dysregulated in patient-derived cells.
  evidence:
  - reference: PMID:28044059
    reference_title: "The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "Dysregulation of ESC/E(Z) complex function could contribute to PMDD."
    explanation: Implicates the ESC/E(Z) complex (which includes EZH2) in PMDD;
      PARTIAL because no specific EZH2 risk variant is established.
- name: BDNF
  gene_term:
    preferred_term: BDNF
    term:
      id: hgnc:1033
      label: BDNF
  association: Risk Factor
  notes: Val66Met polymorphism; a humanized knock-in mouse model shows
    estradiol-dependent PMDD-like behavior in Met carriers.
  evidence:
  - reference: PMID:30356121
    reference_title: "Epigenetic intersection of BDNF Val66Met genotype with premenstrual dysphoric disorder transcriptome in a cross-species model of estradiol add-back."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we show that E2 add-back induces anxiety-like and depression-like
      behavior in Het-Met mice, but not in WT mice"
    explanation: A BDNF Val66Met (Met) knock-in mouse develops anxiety- and
      depression-like behavior on estradiol add-back, recapitulating the
      estradiol-dependent PMDD-like phenotype; the same study found shared
      ESC/E(Z) epigenetic biomarkers across mouse and human PMDD cells.
inheritance:
- name: Multifactorial
  inheritance_term:
    preferred_term: Polygenic inheritance
    term:
      id: HP:0010982
      label: Polygenic inheritance
  description: >
    PMDD is multifactorial/polygenic. Twin studies estimate substantial
    heritability of the stable trait component of premenstrual symptoms, with the
    genetic risk largely distinct from that of major depression. No Mendelian
    pattern, penetrance, or anticipation applies.
  evidence:
  - reference: PMID:9734548
    reference_title: "Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The best-fitting twin-measurement model estimated the heritability of
      the stable component of premenstrual symptoms at 56% and showed no impact of
      family-environmental factors."
    explanation: Provides the heritability estimate (56%) for the stable component
      of premenstrual symptoms.
  - reference: PMID:9734548
    reference_title: "Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The genetic and environmental risk factors for these premenstrual
      symptoms and lifetime major depression are not closely related."
    explanation: Shows the genetic liability for premenstrual symptoms is largely
      distinct from that of major depression.
environmental:
- name: History of Interpersonal Trauma
  notes: Interpersonal trauma and childhood adversity are associated with onset or
    expression of PMDD.
  evidence:
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A history of interpersonal trauma"
    explanation: Identifies interpersonal trauma as a factor influencing onset or
      expression of PMDD.
- name: Chronic Stress
  notes: Perceived stress is greater in the luteal phase in affected individuals
    and may modify symptom expression.
  evidence:
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Perception of the frequency and severity of stress has been reported
      to be greater during the luteal but not the follicular phase of the menstrual
      cycle in women with prospectively confirmed premenstrual dysphoric disorder"
    explanation: Documents heightened luteal-phase stress perception in PMDD.
  - reference: PMID:39397675
    reference_title: "Cumulative stressor exposure predicts menstrual cycle affective changes in a transdiagnostic outpatient sample with past-month suicidal ideation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "greater lifetime stressor exposure may lead to heightened emotional
      reactivity to ovarian hormone fluctuations, elevating the risk of
      psychopathology"
    explanation: Prospective evidence that cumulative lifetime stressor exposure
      heightens emotional reactivity to ovarian-hormone fluctuation, supporting
      stress as a gene-by-environment modifier of PMDD-like symptom severity.
prevalence:
- population: Reproductive-age people with menstrual cycles (confirmed,
    prospectively diagnosed)
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 3200.0
  percentage: 3.2
  evidence:
  - reference: PMID:38199397
    reference_title: "The prevalence of premenstrual dysphoric disorder: Systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pooled prevalence was 3.2 % (95 % confidence intervals: 1.7
      %-5.9 %) for confirmed and 7.7 % (95 % confidence intervals: 5.3 %-11.0 %)
      for provisional diagnosis."
    explanation: Meta-analytic pooled prevalence for prospectively confirmed PMDD.
- population: Reproductive-age people with menstrual cycles (provisional diagnosis)
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 7700.0
  percentage: 7.7
  evidence:
  - reference: PMID:38199397
    reference_title: "The prevalence of premenstrual dysphoric disorder: Systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pooled prevalence was 3.2 % (95 % confidence intervals: 1.7
      %-5.9 %) for confirmed and 7.7 % (95 % confidence intervals: 5.3 %-11.0 %)
      for provisional diagnosis."
    explanation: Meta-analytic pooled prevalence for provisional (retrospective)
      diagnosis, higher than for confirmed diagnosis.
epidemiology:
- name: Affected Population and Age
  description: >
    PMDD occurs in people with ovulatory menstrual cycles during the reproductive
    (premenopausal) years. It does not occur before menarche, during pregnancy or
    other anovulatory states, or after menopause, because cyclical ovulatory
    hormone exposure is the obligate trigger.
  evidence:
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Premenstrual dysphoric disorder, which affects 2%–5% of premenopausal
      women"
    explanation: Establishes the premenopausal (reproductive-age) population in
      which PMDD occurs.
- name: Geographic and Cross-Cultural Distribution
  description: >
    PMDD occurs worldwide and is not culture-bound, with cases documented in
    epidemiological cohorts across multiple continents rather than being confined
    to any single region or culture.
  evidence:
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "premenstrual dysphoric disorder is not a culture-bound syndrome and
      has been found in epidemiological cohorts in the United States"
    explanation: Documents the cross-cultural, non-culture-bound geographic
      distribution of PMDD.
- name: Distribution Across Ethnic Groups
  description: >
    Within a given population, PMDD prevalence is broadly comparable across the
    ethnic groups that have been studied.
  evidence:
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rates are comparable in Caucasians and African Americans in the
      United States"
    explanation: Indicates comparable prevalence across the ethnic groups studied
      within the United States.
progression:
- phase: Luteal-phase symptom onset
  notes: Symptoms emerge in the final week of the luteal phase and remit within a
    few days of the onset of menses, with a symptom-free follicular phase. The
    disorder follows a relapsing-remitting course tied to the menstrual cycle and
    persists across the reproductive lifespan until ovulation ceases (pregnancy,
    menopause, or medical suppression), often worsening toward perimenopause.
  evidence:
  - reference: PMID:38199397
    reference_title: "The prevalence of premenstrual dysphoric disorder: Systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Premenstrual dysphoric disorder is characterised by symptoms
      confined to the premenstrual phase of the menstrual cycle."
    explanation: Confirms the luteal-phase confinement of symptoms that defines the
      cyclical course.
diagnosis:
- name: Prospective Daily Symptom Ratings
  description: >
    Diagnosis requires prospective daily symptom ratings over at least two cycles
    (commonly with the Daily Record of Severity of Problems, DRSP); retrospective
    report is an unreliable predictor. The Carolina Premenstrual Assessment
    Scoring System (C-PASS) operationalizes the DSM-5 criteria for reliable
    diagnosis. DSM-5 requires at least five symptoms in the final luteal week,
    including at least one core affective symptom, with postmenstrual remission and
    clinically significant impairment. There is no diagnostic blood test, biomarker,
    or imaging study.
  evidence:
  - reference: PMID:27523500
    reference_title: "Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "valid diagnosis requires evaluation of prospective daily symptom
      ratings"
    explanation: Establishes prospective daily symptom ratings as the basis of
      valid diagnosis.
  - reference: PMID:27523500
    reference_title: "Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "five symptoms must be present, of which one must be a core emotional
      symptom"
    explanation: Captures the DSM-5 content criterion operationalized by C-PASS.
differential_diagnoses:
- name: Premenstrual Exacerbation (PME) of an Underlying Disorder
  description: >
    Premenstrual worsening of an underlying mood, anxiety, or personality disorder
    (e.g., major depression, bipolar disorder, generalized anxiety). Unlike PMDD,
    symptoms persist through the follicular phase rather than fully remitting after
    menses; this is the key discriminator and the reason prospective charting is
    required.
  distinguishing_features:
  - In PMDD symptoms remit after menses and the follicular phase is symptom-free;
    in PME the underlying disorder persists across the whole cycle.
  evidence:
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the pattern of predictable symptom onset and offset with phases of
      the menstrual cycle remains a key feature distinguishing premenstrual
      dysphoric disorder from other cyclic mood disorders"
    explanation: Identifies the predictable onset/offset pattern as the
      distinguishing feature from other cyclic mood disorders.
- name: Premenstrual Syndrome (PMS)
  description: >
    A milder and more prevalent condition with fewer and less severe affective
    symptoms that does not meet the DSM-5 threshold for PMDD. PMDD lies at the
    severe end of the same continuum of premenstrual symptoms.
  distinguishing_features:
  - PMS is milder, with fewer core affective symptoms and less functional
    impairment than PMDD.
  evidence:
  - reference: PMID:31078196
    reference_title: "Premenstrual Dysphoric Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Premenstrual dysphoric disorder (PMDD) comprises emotional and
      physical symptoms and functional impairment that lie on the severe end of the
      continuum of premenstrual symptoms."
    explanation: Positions PMDD at the severe end of the premenstrual-symptom
      continuum, distinguishing it from milder PMS.
- name: Bipolar Disorder
  description: >
    People with bipolar disorder frequently experience premenstrual mood worsening,
    which can be confused with or co-occur with PMDD. Distinguishing the two is
    clinically important because the first-line PMDD treatment (SSRIs) can provoke
    treatment-emergent manic symptoms in bipolar disorder.
  distinguishing_features:
  - Bipolar mood episodes are not confined to the luteal phase and do not fully
    remit after menses, unlike PMDD.
  - SSRIs, first-line for PMDD, carry a risk of treatment-emergent mania in bipolar
    disorder, so the distinction changes management.
  evidence:
  - reference: PMID:34512419
    reference_title: "Comorbid Premenstrual Dysphoric Disorder and Bipolar Disorder: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a substantial percentage of females with BD experience premenstrual
      mood worsening of varying degrees of severity"
    explanation: Establishes that premenstrual mood worsening is common in bipolar
      disorder, creating diagnostic overlap with PMDD.
  - reference: PMID:34512419
    reference_title: "Comorbid Premenstrual Dysphoric Disorder and Bipolar Disorder: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the first line treatment of PMDD in the general population is
      selective serotonin reuptake inhibitors, which produce risk of
      treatment-emergent manic symptoms"
    explanation: Supports a management-relevant distinction whereby SSRIs used for
      PMDD risk inducing mania in bipolar disorder.
treatments:
- name: Selective Serotonin Reuptake Inhibitors (SSRIs)
  description: >
    First-line pharmacotherapy. SSRIs (e.g., fluoxetine, sertraline, paroxetine)
    are effective given continuously or limited to the luteal phase, and act within
    days in PMDD rather than the weeks needed in depression. Intermittent
    luteal-phase dosing performs comparably to continuous dosing and avoids
    antidepressant withdrawal.
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Serotonergic Involvement
    treatment_effect: MODULATES
    description: SSRIs enhance serotonergic neurotransmission, the rapid-onset
      luteal-phase mechanism implicated in PMDD.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: fluoxetine
      term:
        id: CHEBI:5118
        label: fluoxetine
    - preferred_term: sertraline
      term:
        id: CHEBI:9123
        label: sertraline
  evidence:
  - reference: PMID:39140320
    reference_title: "Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Selective serotonin reuptake inhibitors (SSRIs) are increasingly used
      as a treatment for PMS and PMDD, either administered in the luteal phase or
      continuously."
    explanation: Confirms SSRIs as a treatment given either luteally or
      continuously.
  - reference: PMID:35686687
    reference_title: "Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intermittent (luteal phase) dosing of selective serotonin reuptake
      inhibitors is one treatment strategy for premenstrual syndromes such as
      premenstrual dysphoric disorder. This avoids the risk of the antidepressant
      withdrawal syndrome associated with long-term continuous dosing."
    explanation: Supports intermittent luteal-phase SSRI dosing and its advantage of
      avoiding withdrawal.
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SRI treatment limited to the luteal phase appears to be as effective
      as daily administration"
    explanation: Supports comparable efficacy of luteal-only versus daily SSRI
      dosing.
- name: Drospirenone-Containing Combined Oral Contraceptive
  description: >
    A combined oral contraceptive containing drospirenone with a low ethinyl-
    estradiol dose (24/4 regimen) is approved for PMDD and suppresses the cyclical
    ovarian-steroid fluctuation. Evidence is of low-to-moderate quality with a
    substantial placebo effect.
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Abnormal Sensitivity to Cyclic Ovarian Steroids
    treatment_effect: INHIBITS
    description: By suppressing ovulation, the drospirenone combined oral
      contraceptive flattens the cyclical ovarian-steroid fluctuation that triggers
      symptoms in susceptible individuals.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: drospirenone
      term:
        id: CHEBI:50838
        label: drospirenone
  evidence:
  - reference: PMID:37365881
    reference_title: "Oral contraceptives containing drospirenone for premenstrual syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A combined oral contraceptive containing drospirenone and a low
      oestrogen dose has been approved for treating PMDD in women who choose
      combined oral contraceptives for contraception."
    explanation: Confirms approval of a drospirenone-containing COC for PMDD.
  - reference: PMID:37365881
    reference_title: "Oral contraceptives containing drospirenone for premenstrual syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "COCs containing drospirenone and EE may improve
      premenstrual symptoms that result in functional impairments in women with
      PMDD."
    explanation: Supports symptom improvement; PARTIAL given the low-quality
      evidence and large placebo effect noted in the review.
- name: GnRH Agonist with Hormone Add-Back
  description: >
    For severe or refractory PMDD, gonadotropin-releasing hormone agonists induce
    medical ovarian suppression and are effective for behavioral and physical
    symptoms; hormone add-back is needed to offset the adverse effects of
    hypogonadism, though add-back can transiently reintroduce negative mood in some
    patients.
  therapeutic_modality: PEPTIDE
  target_mechanisms:
  - target: Abnormal Sensitivity to Cyclic Ovarian Steroids
    treatment_effect: INHIBITS
    description: GnRH agonists abolish cyclical ovarian-steroid production, removing
      the hormonal trigger to which susceptible individuals are abnormally
      sensitive; this is the basis of the diagnostic GnRH-suppression paradigm.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: leuprolide
      term:
        id: CHEBI:6427
        label: leuprolide
  evidence:
  - reference: PMID:22764360
    reference_title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While GnRH agonist treatment appears to be effective for both the
      behavioral and physical symptoms of premenstrual syndrome/premenstrual
      dysphoric disorder in the majority of cases, hormone add-back is required to
      reduce the adverse sequelae of long-term hypogonadism."
    explanation: Supports GnRH agonist efficacy and the need for hormone add-back.
- name: Cognitive Behavioral Therapy
  description: >
    Evidence-based psychotherapy used as a non-pharmacological option or adjunct,
    targeting coping and symptom management across the cycle.
  treatment_term:
    preferred_term: cognitive behavioral therapy
    term:
      id: MAXO:0000010
      label: cognitive and behavioral intervention
  evidence:
  - reference: PMID:31078196
    reference_title: "Premenstrual Dysphoric Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Second-line treatments include oral contraceptives containing
      drospirenone, other ovulation suppression methods, calcium, chasteberry, and
      cognitive-behavioral therapy."
    explanation: A clinical review lists cognitive-behavioral therapy among the
      second-line treatment options for PMDD.
  - reference: PMID:19247573
    reference_title: "Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Our review revealed a dearth of evidence providing statistically
      significant CBT intervention effects."
    explanation: A systematic review found only limited evidence for CBT efficacy in
      PMS/PMDD, so support for CBT is partial.
- name: Bright Light Therapy
  description: >
    Luteal-phase bright white light therapy (as used for seasonal affective
    disorder) reduced luteal depression and premenstrual tension versus a dim-light
    placebo in a small double-blind crossover trial in late luteal phase dysphoric
    disorder (the historical name for PMDD). Evidence is limited by small sample
    size.
  treatment_term:
    preferred_term: bright white light therapy
    term:
      id: NCIT:C174524
      label: Bright White Light Therapy
  evidence:
  - reference: PMID:10482337
    reference_title: "A controlled study of light therapy in women with late luteal phase dysphoric disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the active bright white light condition significantly reduced
      depression and pre-menstrual tension scores during the symptomatic luteal
      phase, compared to baseline, while the placebo dim red light condition did
      not"
    explanation: A double-blind crossover trial found bright white light therapy
      reduced luteal depression and premenstrual tension versus dim-light placebo
      in late luteal phase dysphoric disorder (PMDD).
clinical_trials:
- name: NCT03697265
  phase: PHASE_II
  status: COMPLETED
  description: >
    Phase IIb randomised, double-blind, placebo-controlled trial of sepranolone
    (UC1010), an endogenous neurosteroid that antagonizes allopregnanolone's action
    at the GABA-A receptor, dosed during the two weeks before menstruation across
    three cycles in PMDD. Directly tests the allopregnanolone-GABA-A pathophysiology.
  target_phenotypes:
  - preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
  - preferred_term: Emotional Lability
    term:
      id: HP:0000712
      label: Emotional lability
  evidence:
  - reference: clinicaltrials:NCT03697265
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The objective of this phase IIb study is to evaluate the effect and
      safety of Sepranolone (UC1010) on premenstrual symptoms in women with
      Premenstrual Dysphoric Disorder (PMDD)."
    explanation: Documents a mechanism-targeted neurosteroid trial in PMDD aimed at
      the allopregnanolone-GABA-A axis.
mechanistic_hypotheses:
- hypothesis_group_id: allopregnanolone_gabaa_sensitivity
  hypothesis_label: Allopregnanolone-GABA-A Receptor Sensitivity Model
  status: CANONICAL
  description: >
    The dominant mechanistic model holds that PMDD results from impaired GABA-A
    receptor adaptation to the normal luteal fluctuation of the progesterone
    metabolite allopregnanolone, producing a failure of inhibitory neurotransmission
    and downstream corticolimbic dysregulation. This model motivates neurosteroid-
    and GABA-A-targeted drug development (e.g., sepranolone).
  evidence:
  - reference: PMID:36937732
    reference_title: "Role of allopregnanolone-mediated gamma-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PMDD pathophysiology is rooted in GABAA receptor sensitivity changes
      caused by rapid changes in ALLO levels."
    explanation: States the canonical allopregnanolone-GABA-A sensitivity model.
- hypothesis_group_id: esc_ez_epigenetic_setpoint
  hypothesis_label: ESC/E(Z) Epigenetic Set-Point Model
  status: EMERGING
  description: >
    An emerging molecular model proposes that intrinsic dysregulation of the
    ESC/E(Z) chromatin-silencing complex sets the heritable abnormal cellular
    response to ovarian steroids that underlies PMDD. Evidence is from patient-
    derived lymphoblastoid cells; the link to brain mood circuitry is unproven.
  evidence:
  - reference: PMID:28044059
    reference_title: "The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Dysregulation of ESC/E(Z) complex function could contribute to PMDD."
    explanation: States the emerging ESC/E(Z) epigenetic contribution to PMDD.
discussions:
- discussion_id: gap_pmdd_escez_brain_translation
  prompt: >-
    Does the intrinsic ESC/E(Z) epigenetic dysregulation observed in patient-derived
    lymphoblastoid cell lines causally drive the abnormal ovarian-steroid sensitivity
    of brain mood circuitry in PMDD, or is it a peripheral correlate without a direct
    role in the central pathophysiology?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#ESC/E(Z) Epigenetic Dysregulation
  - pathophysiology#Abnormal Sensitivity to Cyclic Ovarian Steroids
  rationale: >-
    The ESC/E(Z) finding is the strongest molecular lead for the heritable
    steroid-sensitivity trait, but it was discovered in peripheral lymphoblastoid
    cells. Whether the same epigenetic difference operates in the corticolimbic
    neurons that generate mood symptoms, and whether it mechanistically sets the
    GABA-A/allopregnanolone sensitivity defect, is unknown. Resolving this would
    determine whether ESC/E(Z) is a tractable central target or a biomarker.
  evidence:
  - reference: PMID:28044059
    reference_title: "The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These findings demonstrate that LCLs from women with PMDD manifest a
      cellular difference in ESC/E(Z) complex function both in the untreated
      condition and in response to ovarian hormones."
    explanation: The cellular difference is demonstrated in peripheral LCLs, leaving
      open its relevance to brain mood circuitry.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
datasets:
references:
- reference: PMID:22764360
  title: "Premenstrual dysphoric disorder: evidence for a new category for DSM-5"
  findings: []
- reference: PMID:36937732
  title: "Role of allopregnanolone-mediated γ-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder: Toward precise targets for translational medicine and drug development."
  findings: []
- reference: PMID:28044059
  title: "The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder."
  findings: []
- reference: PMID:38199397
  title: "The prevalence of premenstrual dysphoric disorder: Systematic review and meta-analysis."
  findings: []
- reference: PMID:31078196
  title: "Premenstrual Dysphoric Disorder."
  findings: []
📚

References & Deep Research

References

5
PMID:22764360
Premenstrual dysphoric disorder: evidence for a new category for DSM-5
No top-level findings curated for this source.
PMID:36937732
Role of allopregnanolone-mediated γ-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder: Toward precise targets for translational medicine and drug development.
No top-level findings curated for this source.
PMID:28044059
The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder.
No top-level findings curated for this source.
PMID:38199397
The prevalence of premenstrual dysphoric disorder: Systematic review and meta-analysis.
No top-level findings curated for this source.
PMID:31078196
Premenstrual Dysphoric Disorder.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
1. Disease Information
claude-haiku-4-5-20251001, claude-opus-4-8[1m] 19 citations 2026-06-24T17:45:03.025441

1. Disease Information

Overview. Premenstrual dysphoric disorder (PMDD) is a severe, cyclical mood disorder defined by clinically significant affective and somatic symptoms that emerge in the luteal phase (roughly the week before menses), remit within a few days of bleeding onset, and are essentially absent in the follicular phase. It is best understood not as a hormone excess or deficiency state but as an abnormal central nervous system sensitivity to normal cyclical ovarian-steroid fluctuation — the symptoms are triggered by physiological progesterone/estradiol changes that are well tolerated by unaffected women. Think of it less like a thermostat set too high and more like a smoke detector wired to go off at the ordinary warmth of cooking dinner: the stimulus is normal, the alarm is not.

Key identifiers: | Resource | ID | |---|---| | MONDO | MONDO:0005905 (premenstrual dysphoric disorder) [verify exact ID in local MONDO cache] | | DSM-5-TR | 625.4 (under Depressive Disorders) | | ICD-11 | GA34.41 (genitourinary chapter, cross-listed under depressive disorders 6E40 in some mappings) | | ICD-10 | N94.3 (premenstrual tension syndrome) / F32.81 (US clinical PMDD code) | | DOID | DOID:9881 [verify] | | MeSH | D065446 "Premenstrual Dysphoric Disorder" | | OMIM | None — not a Mendelian disorder (no single-gene OMIM entry) | | Orphanet | Not a rare disease; not an ORPHA leaf |

Synonyms / alternative names: Late luteal phase dysphoric disorder (LLPDD — the DSM-III-R/DSM-IV appendix name); severe premenstrual syndrome; premenstrual dysphoria. Distinguish from premenstrual syndrome (PMS), a milder and more prevalent condition, and from premenstrual exacerbation (PME) of an underlying disorder.

Data derivation: Disease-level. PMDD is defined by prospective daily symptom ratings (DSM-5 requires ≥2 symptomatic cycles documented in real time), not by EHR diagnosis codes or biomarkers. Aggregated knowledge comes from cohort studies, RCTs, and the NIMH intramural hormone-manipulation program (Schmidt/Rubinow/Goldman).

Sources: ICD-11 recognition – Asarina/Schroll 2022 AOGS; Diagnostic validity revisited 2023 (PMC10711063)

2. Etiology

Primary causal model. PMDD is a multifactorial, gene-by-hormone-by-environment disorder. The unifying mechanistic insight comes from the landmark NIMH ovarian-suppression studies: when ovarian function is shut off with the GnRH agonist leuprolide, women with PMDD lose their symptoms; when estradiol or progesterone is then added back, symptoms recur — while unaffected women show no mood change to identical manipulations.

"In women with premenstrual syndrome, the occurrence of symptoms represents an abnormal response to normal hormonal changes." — Schmidt PJ et al., N Engl J Med 1998 (PMID: 9435325 [verified via search]).

A 2025 replication/extension confirmed the differential-sensitivity finding (PubMed 41030005 [verified via search]).

Genetic risk factors: - Heritability ~30–56% for the stable trait component of premenstrual symptoms (Virginia/UK twin registries; Kendler et al. estimated ~56% for the stable component). [verified via search] - ESR1 (estrogen receptor alpha) — four intron-4 SNPs differ between PMDD cases and controls; the association was strongest in carriers of the COMT Val/Val genotype (Huo L et al., Biol Psychiatry 2007, PMID: 17599809 [verified via search]). - ESC/E(Z) (Extra Sex Combs / Enhancer of Zeste) epigenetic complex — the strongest molecular lead. Lymphoblastoid cell lines from PMDD women show intrinsically dysregulated expression of >half of ESC/E(Z) genes, both untreated and in response to estradiol/progesterone (Dubey N et al., Mol Psychiatry 2017, PMID: 28044059 [verified via search]). - BDNF Val66Met — a humanized Met-knock-in mouse recapitulates PMDD-like anxiety/depression behavior on estradiol add-back (cross-species model, PMC7042769 [verified via search]).

Environmental / non-genetic risk factors: history of trauma/childhood adversity and PTSD; high perceived stress; current/past mood or anxiety disorder; smoking; high BMI; younger-to-mid reproductive age. Cyclical hormone exposure itself is the obligate trigger (PMDD does not occur in anovulatory states, pregnancy, or after menopause).

Protective factors: Anything that abolishes ovulatory cyclicity is mechanistically protective — pregnancy, lactational amenorrhea, menopause, continuous ovulation suppression (GnRH agonists, some COCs). No validated protective genetic allele is established.

Gene–environment interaction: The core model is a G×E interaction — heritable CNS steroid sensitivity (ESC/E(Z), ESR1, BDNF) × the normal cyclical hormonal "environment." Stress reactivity is amplified, plausibly via poor allopregnanolone–GABA control of the HPA axis.

3. Phenotypes (HPO suggestions)

PMDD is largely behavioral/psychiatric; HPO coverage is coarse. Core symptoms cluster as affective, then behavioral/cognitive, then somatic. All are episodic/cyclical (luteal-phase-locked), recurrent, adult-onset, remitting at menses.

Phenotype Category Suggested HPO Notes/frequency
Affective lability / mood swings Behavioral HP:0000713 Behavioral abnormality (no precise term) Cardinal; required core symptom
Irritability / anger Behavioral HP:0000737 Irritability Most distinguishing PMDD symptom
Depressed mood / hopelessness Behavioral HP:0000716 Depression / Depressivity Common
Anxiety / tension / "on edge" Behavioral HP:0000739 Anxiety Common
Anhedonia / decreased interest Behavioral HP:0100750 Apathy / HP:0000716 Frequent
Difficulty concentrating Cognitive HP:0000752 Hyperactivity? (poor fit) / use HP:0100543 Cognitive impairment cautiously Frequent
Fatigue / lethargy / low energy Constitutional HP:0012378 Fatigue Frequent
Appetite change / food cravings Constitutional HP:0002591 Polyphagia / HP:0004396 Poor appetite Common
Hypersomnia or insomnia Sleep HP:0002360 Sleep abnormality Common
Feeling overwhelmed / loss of control Behavioral HP:0000713 (no precise term) Required-domain symptom
Breast tenderness Somatic HP:0100650 Mastodynia? (verify) Physical symptom criterion
Bloating / weight-gain sensation Somatic HP:0003270 Abdominal distention Physical symptom criterion
Joint/muscle pain, headache Somatic HP:0002829 Arthralgia / HP:0002315 Headache Physical symptom criterion
Suicidal ideation (luteal) Behavioral HP:0031589 Suicidal ideation Elevated risk; clinically critical

Severity: moderate–severe by definition (must cause marked impairment in work, relationships, or functioning). Frequency among affected: ≥5 of 11 symptom domains required per cycle, with ≥1 from the core affective set. QoL impact: substantial — comparable functional impairment to major depression during the symptomatic window; elevated absenteeism, interpersonal conflict, and suicidality.

4. Genetic / Molecular Information

  • No causal Mendelian gene. PMDD is polygenic/complex.
  • Top molecular lead — ESC/E(Z) epigenetic regulatory complex (PRC2-related; includes EZH2, EED, SUZ12 and partners). Intrinsic transcriptional dysregulation in PMDD cells, differentially modulated by ovarian steroids (Dubey 2017, PMID 28044059). Subgenual cingulate rCBF correlates with ESC/E(Z) gene expression (Transl Psychiatry 2021, s41398-021-01328-4 [verified via search]).
  • ESR1 (estrogen receptor α; HGNC:3467) — intronic SNP associations (Huo 2007, PMID 17599809).
  • COMT Val158Met (HGNC:2228) — modifies the ESR1 effect (Val/Val carriers).
  • BDNF Val66Met (HGNC:1033) — model-organism epigenetic interaction with estradiol (PMC7042769).
  • GABA-A receptor subunits — functional/transcriptional, not classic risk variants: lower δ-subunit (GABRD) mRNA in luteal phase, correlated with amygdala hyperactivity (search 2023/2025; Transl Psychiatry s41398-025-03465-6 [verified via search]).
  • Variant classification / allele frequencies / somatic vs germline: Not applicable — these are common germline susceptibility polymorphisms, not pathogenic/ACMG-classified variants; no ClinVar pathogenic entries; no somatic/COSMIC component.
  • Epigenetics: Central — ESC/E(Z) is a histone-methylation (chromatin) regulatory complex; steroid-responsive epigenetic reprogramming is the leading mechanistic frame.
  • Chromosomal abnormalities: None.

5. Environmental Information

  • Environmental/toxic factors: No established chemical toxicant cause. Smoking is associated with higher PMS/PMDD risk.
  • Lifestyle: Stress, poor sleep, smoking, high BMI, alcohol associate with severity; exercise and some dietary factors (calcium) associate with milder symptoms (evidence modest).
  • Infectious agents: Not applicable — PMDD is not infectious.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

  1. Heritable CNS steroid sensitivity (ESC/E(Z) epigenetic dysregulation; ESR1/COMT/BDNF variants) sets an abnormal substrate. [upstream trigger]
  2. Normal luteal-phase rise then fall of progesterone, and its neuroactive metabolite allopregnanolone (ALLO; CHEBI:50169 — verify), a potent positive allosteric modulator of the GABA-A receptor (GO:1902476 chloride transmembrane transport; GABA-A is the major inhibitory ionotropic receptor).
  3. Dysregulated GABA-A receptor plasticity / sensitivity to ALLO — paradoxical or blunted inhibitory response, partly via altered δ-subunit (GABRD) expression. The system fails to "tune" GABA-A as ALLO swings. [core mechanism]

PMDD reflects "dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle." — Hantsoo/Epperson-lineage reviews; Frontiers Psychiatry 2023 (PMC10017536, doi:10.3389/fpsyt.2023.1140796 [verified via search]).

  1. Impaired top-down emotional regulation: luteal-phase amygdala and insula hyperreactivity to emotional/social stimuli with reduced anterior cingulate / prefrontal control (Gingnell et al. 2012, PMID: 22814368 [verified via search]; recent fMRI systematic review, Frontiers 2026). δ-GABRD mRNA inversely tracks amygdala activation.
  2. HPA-axis stress dysregulation from poor ALLO–GABA control → heightened stress sensitivity.
  3. Serotonergic involvement: rapid SSRI efficacy (days, not weeks) suggests SSRIs act partly by increasing ALLO synthesis (3α-HSD modulation), linking the serotonin and neurosteroid systems. [downstream/therapeutic node]
  4. Output: luteal affective/cognitive/somatic symptoms → remission at menses as progesterone/ALLO fall.

GO term suggestions: GO:0007268 (chemical synaptic transmission), GO:1902711 (positive regulation of GABA-A receptor activity — verify), GO:0051384 (response to glucocorticoid), GO:0030518 (intracellular steroid hormone receptor signaling), GO:0006classnonsense — use GO:0043401 (steroid hormone mediated signaling). CL terms: CL:0000540 (neuron), CL:0000598 (pyramidal neuron), CL:0000617 (GABAergic neuron — verify), CL:0000125 (glial cell). Cell types involved: amygdalar/cortical pyramidal neurons and GABAergic interneurons; circulating monocytes used as accessible biomarker tissue.

Molecular profiling: RNA-seq of LCLs (ESC/E(Z), Dubey 2017); monocyte GABA-A subunit transcription (2025); steroid metabolome under GnRH suppression (Transl Psychiatry tp2017146 [verified via search]). No robust proteomic/metabolomic clinical signature yet beyond neurosteroid ratios (ALLO, isoallopregnanolone/ISO).

7. Anatomical Structures Affected

  • Organ/system: Central nervous system (primary) and the hypothalamic-pituitary-ovarian + HPA axes (endocrine). PMDD is a brain disorder triggered by ovarian output.
  • UBERON terms: UBERON:0001876 amygdala, UBERON:0001870 frontal cortex / UBERON:0002756 cingulate cortex (subgenual/ACC), UBERON:0002021 insula (verify), UBERON:0001954 hippocampus/parahippocampal, UBERON:0001898 hypothalamus, UBERON:0000992 ovary (trigger source).
  • Tissue/cell: corticolimbic neurons (pyramidal + GABAergic interneurons).
  • Subcellular (GO CC): GO:0034707 (chloride channel complex — GABA-A receptor), synaptic membrane (GO:0097060); steroid signaling in nucleus/cytoplasm.
  • Lateralization: functional imaging often emphasizes right amygdala, but the disorder is bilateral/non-lateralized clinically.

8. Temporal Development

  • Onset: reproductive years; typically mid-20s to 30s, often worsening with age toward perimenopause; requires ovulatory cycles.
  • Onset pattern: chronic-recurrent with sharply episodic, cycle-locked flares.
  • Course: relapsing-remitting, tied 1:1 to the menstrual cycle — symptoms in the late luteal phase, remission within a few days of menses, symptom-free follicular phase.
  • Duration: persists across the reproductive lifespan unless treated or until ovulation ceases (pregnancy, menopause, suppression).
  • Critical periods / windows: the luteal phase is the intervention window — enables symptom-onset or luteal-only SSRI dosing; perimenopause is a vulnerability window (erratic hormone swings); menopause is naturally curative.

9. Inheritance and Population

  • Prevalence: meta-analytic pooled ~3.2% for confirmed (prospectively diagnosed) PMDD and ~7.7% for provisional diagnosis (J Affect Disord 2024, S0165032724000764 [verified via search]); commonly cited range 2–5% (up to 8% with looser criteria) of reproductive-age women.
  • Incidence: not well defined (cyclical disorder, not incident-event based).
  • Inheritance pattern: multifactorial / polygenic; heritability ~30–56% for the stable trait (twin studies). No Mendelian pattern, penetrance, anticipation, founder effect, or carrier frequency applies.
  • Sex ratio: essentially exclusively in menstruating individuals (people assigned female with ovulatory cycles); reproductive-age window.
  • Geographic distribution: worldwide; prevalence estimates vary by criteria strictness (prospective vs retrospective) more than by geography.

10. Diagnostics

  • Gold standard: prospective daily symptom ratings over ≥2 consecutive cycles — there is no diagnostic blood test, biomarker, or imaging study. The Daily Record of Severity of Problems (DRSP) (21 items, 11 domains) is the validated instrument; the Carolina Premenstrual Assessment Scoring System (C-PASS) operationalizes DSM-5 scoring (Eisenlohr-Moul TA et al., Am J Psychiatry 2017, PMID: 27523500 [verified via search]).
  • DSM-5-TR criteria: ≥5 symptoms in the final luteal week, ≥1 from the core set (marked affective lability, irritability/anger, depressed mood/hopelessness, anxiety/tension), with remission after menses, confirmed prospectively, causing significant impairment, not merely an exacerbation of another disorder (Epperson CN et al., Am J Psychiatry 2012;169(5):465–475, PMID: ~22764360 [verify before use]).
  • ICD-11 (GA34.41): ≥1 affective + ≥1 somatic/cognitive symptom, cyclically luteal, distressing, prospectively patterned.
  • Labs/imaging: used only to exclude mimics (thyroid panel, CBC for anemia; no PMDD-specific value). Research-only: neurosteroid ratios (ALLO, ISO), fMRI amygdala reactivity.
  • Differential diagnosis (rule out via charting): premenstrual exacerbation (PME) of major depression, bipolar disorder, generalized anxiety, or borderline personality (these persist through the follicular phase — the key discriminator); PMS (milder, fewer affective symptoms); thyroid disease; perimenopausal mood disorder.
  • Genetic/omics testing: not clinically indicated.

11. Outcome / Prognosis

  • Mortality: PMDD is not directly lethal, but luteal-phase suicidality is markedly elevated — a critical safety concern. No survival/5-year metrics apply.
  • Morbidity: substantial functional disability during symptomatic windows — occupational impairment, relationship conflict, reduced QoL; cumulative burden across decades of cycles.
  • Course: chronic-relapsing until reproductive cessation; tends to worsen in perimenopause and resolve at menopause or with definitive ovulation suppression.
  • Prognosis with treatment: good — most patients respond to SSRIs and/or ovulation suppression. Prognostic factors: comorbid mood/anxiety disorders and trauma history predict worse course; clear cyclicity predicts good treatment response.

12. Treatment (MAXO/CHEBI suggestions)

First-line — SSRIs (rapid, often within days; can be continuous, luteal-phase, or symptom-onset dosing): - Fluoxetine (CHEBI:5118), sertraline (CHEBI:9123), paroxetine (CHEBI:7936 verify), escitalopram (CHEBI:36791 verify). FDA-approved for PMDD: fluoxetine, sertraline, paroxetine CR. - MAXO: MAXO:0000058 (pharmacotherapy — verify; or NCIT:C15986 Pharmacotherapy); therapeutic_modality SMALL_MOLECULE. - Evidence: intermittent (luteal) SSRIs effective (meta-analysis PMC10074750 [verified via search]); Cochrane SSRI review PMC11323276.

First-line/second-line — combined oral contraceptives: drospirenone + ethinylestradiol 20 µg, 24/4 regimen (e.g., YAZ) is FDA-approved and the best-evidenced COC, though placebo effect is large (Cochrane, Ma S 2023, CD006586.pub5 [verified via search]). CHEBI: drospirenone (CHEBI:50838 verify), ethinylestradiol (CHEBI:4903 verify).

Adjunct/other: SNRIs (venlafaxine); calcium supplementation; CBT/dialectical-behavior-informed therapy (MAXO behavioral therapy); lifestyle measures.

Third-line / severe-refractory — ovulation suppression: GnRH agonists (leuprolide) with estradiol/progesterone add-back; rarely bilateral oophorectomy ± hysterectomy as definitive surgical cure for refractory disease (MAXO surgical procedure MAXO:0000004).

Investigational (mechanism-targeted neurosteroid therapies): - Sepranolone (UC1010 / isoallopregnanolone, GABA-A modulating steroid antagonist) — luteal-phase Phase IIb in PMDD (NCT03697265 [verified via search], Asarina Pharma). - Ulipristal acetate (selective progesterone receptor modulator) — studied for PMDD symptom suppression. - Allopregnanolone/GABA-A–directed agents under translational development (Frontiers 2023, PMC10017536).

13. Prevention

  • Primary prevention: none established (no way to prevent the underlying trait). Risk-factor modification (stress reduction, smoking cessation) may lower severity.
  • Secondary prevention: early recognition via prospective charting; treat before functional/safety impact accrues.
  • Tertiary prevention: suicidality risk management during luteal windows; ovulation suppression to prevent recurrent flares.
  • Immunization / public health / prophylaxis: not applicable (non-infectious). Genetic counseling/screening: not indicated (polygenic, no actionable variant).

14. Other Species / Natural Disease

  • Taxonomy: human disorder (NCBITaxon:9606). No naturally occurring PMDD in other species (requires self-reported cyclical mood symptoms).
  • OMIA / veterinary: not applicable.
  • Comparative biology: ovarian-cycle neurosteroid–GABA-A signaling is evolutionarily conserved in rodents, which underpins the model systems below, but the syndrome is human.
  • Zoonotic: not applicable.

15. Model Organisms

  • Mouse, induced hormonal models — the workhorse. GnRH-suppression + steroid add-back paradigms and progesterone-withdrawal models reproduce ALLO/GABA-A δ-subunit plasticity and anxiety/depression-like behavior (MGI; in vivo).
  • BDNF Val66Met humanized knock-in mouse — estradiol add-back induces PMDD-like anxiety/depression behavior in Met carriers, with parallel epigenetic changes (cross-species LCL↔mouse model, PMC7042769 [verified via search]). evidence_source: MODEL_ORGANISM.
  • Rat "liver-qi invasion" PMDD-irritability model — used in GABA-A-Rα4 amygdala/hippocampus studies (PMC10008490 [verified via search]).
  • In vitro / human cells: lymphoblastoid cell lines (LCLs) from PMDD patients vs controls — the ESC/E(Z) RNA-seq discovery platform (Dubey 2017, PMID 28044059). evidence_source: IN_VITRO. Circulating monocytes as accessible GABA-A-subunit readout.
  • Recapitulation/limitations: rodent models capture the neurosteroid–GABA-A mechanism and behavioral output well but cannot model the subjective affective/cognitive criteria; LCLs/monocytes are peripheral surrogates for inaccessible brain tissue — flag as HUMAN_MODEL_MISMATCH where translational validity is the open question.

Key Citations (verify all PMIDs with just fetch-reference before YAML use)

Claim Citation PMID Status
Abnormal response to normal hormone changes Schmidt PJ et al., NEJM 1998 9435325 verified via search
ESC/E(Z) epigenetic dysregulation Dubey N et al., Mol Psychiatry 2017 28044059 verified via search
ESR1 association Huo L et al., Biol Psychiatry 2007 17599809 verified via search
C-PASS diagnostic system Eisenlohr-Moul TA et al., Am J Psychiatry 2017 27523500 verified via search
Amygdala reactivity across cycle Gingnell M et al. 2012 22814368 verified via search
DSM-5 new category rationale Epperson CN et al., Am J Psychiatry 2012 ~22764360 verify
Differential-sensitivity replication (2025 NIMH replication) 41030005 verified via search
Prevalence meta-analysis J Affect Disord 2024 (PMC via S0165032724000764) verified via search
ALLO–GABA-A pathogenesis review Frontiers Psychiatry 2023 PMC10017536 verified via search

Sources: - Schmidt 1998 NEJM – differential behavioral effects - Dubey 2017 ESC/E(Z) – PMC5495630 | NIMH summary - Huo 2007 ESR1 – PubMed 17599809 - Eisenlohr-Moul 2017 C-PASS – PubMed 27523500 | C-PASS PMC5205545 - Gingnell 2012 amygdala – PubMed 22814368 - ALLO–GABA-A review 2023 – PMC10017536 | GABA-A dysregulated sensitivity – ScienceDirect - Prevalence meta-analysis 2024 – ScienceDirect - Diagnostic validity revisited 2023 – PMC10711063 - From Genes to GABA review – PMC10176022 - Cochrane drospirenone 2023 – CD006586.pub5 - Intermittent SSRI meta-analysis – PMC10074750 - Sepranolone trial – NCT03697265 - BDNF Val66Met cross-species model – PMC7042769 - GABA-A monocyte transcription 2025 – Transl Psychiatry - Steroid metabolome under GnRH suppression – tp2017146 - ICD-11 recognition – Schroll 2022 AOGS

Quick orientation for the curator

sup — the one-sentence version of this whole thing: PMDD isn't "too much hormone," it's a brain that reads a perfectly normal hormone tide as a threat. The single most important framing for the dismech pathophysiology causal chain is the Schmidt leuprolide experiment (PMID 9435325) → differential CNS sensitivity → ESC/E(Z) epigenetic setpoint (PMID 28044059) → ALLO/GABA-A receptor plasticity failure → corticolimbic dysregulation (amygdala↑, ACC↓) → luteal symptoms that vanish at menses. Two big landmines I'd flag before you commit YAML: (1) keep PMDD cleanly separated from plain PMS and from PME (premenstrual exacerbation) — that's the classic Named-Entity-Confusion trap here; and (2) several of my CHEBI/HPO/GO IDs above are "best guess, verify" — run just validate-terms-file on them, because the affective symptoms genuinely don't have crisp HPO homes and it's easy to grab a term that doesn't exist.

I have one PMID I couldn't fully nail down this session — the Epperson 2012 DSM-5 paper (I'm ~confident it's 22764360 but didn't see it printed in results), so just fetch-reference that one specifically before it goes in.